Patricia Imbach‐Weese
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Biochemical and Molecular Research, Hippo pathway signaling and YAP/TAZ, Multiple Myeloma Research and Treatments
Most-Cited Works
- → Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation(2013)463 cited
- → The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition(2022)43 cited
- → Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field(2023)33 cited
- → Podocyte EphB4 signaling helps recovery from glomerular injury(2012)28 cited
- → Identification and optimisation of a 4′,5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors(2015)21 cited
- → Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors(2015)17 cited
- → Corrigendum to “Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation” [Bioorg. Med. Chem. Lett. 23 (2013) 3741–3748](2013)17 cited
- → Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor(2022)12 cited
- → Front Cover: The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition (ChemMedChem 19/2022)(2022)1 cited